TY - JOUR
T1 - Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer
AU - Capasso, I.
AU - Santoro, Angela
AU - Lucci Cordisco, Emanuela
AU - Perrone, E.
AU - Tronconi, F.
AU - Catena, U.
AU - Zannoni, Gian Franco
AU - Scambia, G.
AU - Fanfani, Francesco
AU - Lorusso, D.
AU - Duranti, S.
PY - 2023
Y1 - 2023
N2 - : This review provides a comprehensive update on recent evidence regarding gynecologic tumors associated with Lynch Syndrome (LS). Endometrial cancer (EC) and ovarian cancer (OC) are the first and second most common gynecologic malignancies in developed countries, respectively, and LS is estimated to be the hereditary cause in 3% of both EC and OC. Despite the increasing evidence on LS-related tumors, few studies have analyzed the outcomes of LS-related EC and OC stratified by mutational variant. This review aims to provide a comprehensive overview of the literature and comparison between updated international guidelines, to help outline a shared pathway for the diagnosis, prevention, and management of LS. Through the widespread adoption of the immunohistochemistry-based Universal Screening, LS diagnosis and identification of mutational variants could be standardized and recognized by international guidelines as a feasible, reproducible, and cost-effective method. Furthermore, the development of a better understanding of LS and its mutational variants will support our ability to better tailor EC and OC management in terms of prophylactic surgery and systemic treatment in the light of the promising results shown by immunotherapy.
AB - : This review provides a comprehensive update on recent evidence regarding gynecologic tumors associated with Lynch Syndrome (LS). Endometrial cancer (EC) and ovarian cancer (OC) are the first and second most common gynecologic malignancies in developed countries, respectively, and LS is estimated to be the hereditary cause in 3% of both EC and OC. Despite the increasing evidence on LS-related tumors, few studies have analyzed the outcomes of LS-related EC and OC stratified by mutational variant. This review aims to provide a comprehensive overview of the literature and comparison between updated international guidelines, to help outline a shared pathway for the diagnosis, prevention, and management of LS. Through the widespread adoption of the immunohistochemistry-based Universal Screening, LS diagnosis and identification of mutational variants could be standardized and recognized by international guidelines as a feasible, reproducible, and cost-effective method. Furthermore, the development of a better understanding of LS and its mutational variants will support our ability to better tailor EC and OC management in terms of prophylactic surgery and systemic treatment in the light of the promising results shown by immunotherapy.
KW - endometrial cancer
KW - immunohistochemistry markers
KW - lynch syndrome
KW - microsatellite instability
KW - mismatch repair deficiency
KW - ovarian cancer
KW - endometrial cancer
KW - immunohistochemistry markers
KW - lynch syndrome
KW - microsatellite instability
KW - mismatch repair deficiency
KW - ovarian cancer
UR - https://publicatt.unicatt.it/handle/10807/229358
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85149780902&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149780902&origin=inward
U2 - 10.3390/cancers15051400
DO - 10.3390/cancers15051400
M3 - Article
SN - 2072-6694
VL - 15
SP - 1400-N/A
JO - Cancers
JF - Cancers
IS - 5
ER -